Molecular pharmacology of inflammation

J.M. Pfeilschifter

In collaboration with B. Brüne (Frankfurt, Germany); R. Brunkhorst (Frankfurt, Germany); J. Couchman (London, England); S-E. Dahlen (Stockholm, Sweden); J. Eble (Münster, Germany); D. Fabbro (Basel, Switzerland); J. Fischer (Düsseldorf, Germany); U. Forstermann (Mainz, Germany); H. Geiger (Frankfurt, Germany); G. Geisslinger (Frankfurt, Germany); A. Görlach (München, Germany); G. Grammatikos (Thessaloniki, Greece); H-J. Gröne (Heidelberg, Gernany); L.-O. Hattenbach (Ludwigshafen, Germany); A. Huwiler (Bern, Switzerland); R.V. Iozzo (Phildadelphia, USA): P-J. Jacobsson (Stockholm, Sweden); B. Kleuser (Potsdam, Germany); H-J. Pavenstädt (Münster, Germany); W. Pfeilschifter (Frankfurt, Germany); R. Sader (Frankfurt, Germany); L. Sorokin (Münster, Germany); H. Steinmetz (Frankfurt, Germany); C. Thiemermann (London, England); I. Wittig (Frankfurt, Germany); M. Young (Bethesda, USA); S. Zeuzem (Frankfurt, Germany); B. Zwissler (Frankfurt, Germany)

Introduction

Our group is interested in the molecular mechanisms of inflammation that underlie the so-called cardinal symptoms of inflammation including redness, heat, swelling and pain.These symptoms are due to vasodilatation in pericapillary beds and increased vascular permeability to solutes, followed rapidly by neutrophil and other inflammatory cell infiltration. The complexity of this stage is r